Tscan Therapeutics Inc

NASDAQ:TCRX   4:00:00 PM EDT
1.44
-0.02 (-1.37%)
7:47:59 PM EDT: $1.51 +0.07 (+4.86%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)80.37M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$1.31 Million
Adjusted EPS-$0.33
See more estimates
10-Day MA$1.52
50-Day MA$1.47
200-Day MA$3.04
See more pivots

Tscan Therapeutics Inc Stock, NASDAQ:TCRX

830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees: 194

Description

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.